Marwah Medicine

NEET PG, NEETSS

NEET SS 2021 |Exam dates (13th and 14th November 2021) | Exam Syllabus| Exam pattern

Status   Date Form release   1st September 2021 Registration started at nbe.edu.in   22nd September 2021 Candidates have to pay 4250 as NEET SS 2021 fees instead of usual 3750 Cutoff date for eligibility is November 30th 2021   22nd September 2021 Correction window   16 to 18th October 2021 Issuance of NEET SS admit card   5th November 2021 Examination date   13 and 14th November 2021 Result declaration   By 30th November 2021 Preparation strategy for NEET SS The syllabus is expansive and vast. Trying to read entire Harrison line by line is like trying to swim in the high seas. Obviously you can swim but will tire out soon and the chances of going down will increase. Hence it is advised to use the contents of NEET SS preparation by Dr Marwah well before the examination You would have noticed that environmental medicine, Geriatric medicine and Toxicology is being increasingly asked in the SS exam and the same is covered in the app by Deepak Marwah extensively. Since the medium of instruction of app is Hinglish it will be easy for you to grasp and move on with the concepts. The strike rate in any exam of candidates increases if they have studied the content in their mother tongue. You can check out the content in free section of the app before you purchase so that you know what you are investing in. I recommend you compare the subject delivery with other apps and then invest your hard-earned money. Now making a timetable is important. 80 percent of those who make a timetable however fail to adhere to it. So make micro achievable target and stick to them so that gradually you are able to increase your knowledge base. When you attempt MCQ for first time read the explanation of the questions in limited time frame rather than in a relaxed fashion. This is because in the actual exam you need fast reflexes. It is not the lack of knowledge but the ability to strike the correct answer that matters.  The content in the NEET SS Medicine by Deepak Marwah is crisp and concise and helps you develop that analytical skill necessary for the examination.  Now note down the explanation of each question in one single line ( just one line only ) as a summary point in a separate 100-page register for each subtopic you will read. Now coming to content of each page of the register you will have 20 points say in cardiology arrythmias that have been asked in last 4 years.  When you read those points again and again you will come to know that which topics are frequently repeated and which topics are asked. Now since you know what are the high yield topics that come in the exam and what is the correct answer you are only 25 percent ready to face the exam. Now go through the pdf of lecture notes from the app and do them thoroughly with markings on those topics which you found difficult. Repeated listening to topics of high yield like Electrolyte imbalance or NMO core clinical criteria will make you improve your strike rate in this examination. This step is the most important step in your journey for clearing the MCI screening examination. You have now reached 50 percent of journey but wait there is more to punching practice to be done. In case you are the one who is starting early for NEET SS preparation and love to make you own notes then be careful to not fill up registers with voluminous data that becomes impossible to revise. It has to be crisp and precise. Solve Mock Tests regularly and here lets be honest people tend to use multiple sources and end up being no where. Stick to one source and do it honestly and regularly. You will gradually realize that you marked a question correct in first hunch but still ended up changing the option at the last moment. You need to give time to one source and fine tune your skills gradually. You have to take that decision whether your hunch is always correct / correct 50 percent of time or never correct. My hunch is mostly correct and so I always rely on marking the question where the three options are alien to me. This helps you increase your score over your rivals. So guys if you have gone through these 11 steps you would realize that these are smart study steps are the key to success that has enabled many NEET SS aspirants to crack the exam. Whatever happens and whichever rank you get remember that your NEET SS preparation will never go in vain. Smart work coupled with dedication and hard work will make the best strategy for the preparation of the exam. Make this year the best year of your life using the best app for NEETSS preparation. Prepare prudently with Dr Marwah NEET SS General Medicine pack which is a course curated exclusively for NEET SS aspirants like you to ace the final exams and bag your dream super-specialty seat. It includes everything you need – Video Lectures Plus excellent Q-bank and Test Series to top it up.  Examination pattern The exam duration of NEET SS 2021 has been decreased to 150 minutes in which 150 questions will be asked. The questions will be from PG level books like for NEET SS Cardiology or Rheumatology the questions will be Harrison based. Hence to prepare for the same you can use app or book. The Complete review of medicine 5th edition by Deepak marwah is one of the better books to prepare for this examination. The stem of lot of questions has the same DNA as NEET PG entrance exam and hence you can cover Harrison reading with this MCQ book.  However, if you are not a bookish person the same content is available in the app format as well and covers all the important topics […]

FMGE, INICET, NEET PG, NEET PG 2025

NON-INVASIVE VENTILATION

This is a high yield topic for your forth coming exams and must know from medical perspective. Lets focus on indications and contraindications for NIV. Indications for Non-Invasive Ventilation (NIV) Mnemonic: “COPD CAN Breathe” COPD exacerbation with hypercapnia and respiratory acidosis. Cardiogenic pulmonary oedema with respiratory distress. Chronic respiratory failure (neuromuscular diseases, obesity hypoventilation syndrome, chest wall deformities). Acute hypoxemic respiratory failure (selected patients, PaO₂/FiO₂ < 200). Non-invasive support post-extubation to prevent reintubation. Breathe (palliative care with DNI orders to ease dyspnea). Contraindications for Non-Invasive Ventilation (NIV) Mnemonic: “CRASH FACE” Cardiac or respiratory arrest. Risk of aspiration due to inability to protect the airway. Active vomiting or copious secretions. Severe facial trauma, burns, or structural abnormalities. Hemodynamic instability or life-threatening arrhythmias. FACE: Failed mask fit due to anatomy or burns. Agitation or inability to cooperate. Critical acidosis (pH < 7.15). Extreme hypoxemia requiring invasive ventilation. #NEETPG #INICET #FMGE

COVID-19, Medical, NEET PG

SARS COV-2 Assessment and Treatment Guidelines

The global fight against COVID-19 continues to evolve, with new research and clinical evidence shaping updated treatment guidelines. Here, we provide an overview of the latest recommendations for managing COVID-19, focusing on key advancements in therapies, preventive strategies, and patient management. Assessment of Clinical severity of COVID 19 to target treatments Mild to moderate COVID 19 spO2 > 94% on room air and not needing supplemental oxygen but with risk factors for progression to severe disease, hospitalization or death   Severe COVID -19 Sp02 < 94 % on room air or needing low flow supplemental oxygen   Critical COVID -19   Needing high flow oxygen or NIV Critical COVID-19   Needing mechanical ventilation or ECMO   Risk factors: Age > 60 years, BMI > 25 years, hypertension, cardiovascular disease, Chronic lung disease, chronic kidney disease, immunocompromised states Treatment Mild to moderate COVID-19 with risk factors for progression to severe disease, hospitalization or death Nirmatrelvir Plus ritonavir Must be started within 5 days of onset of symptoms Molnupiravir Must be started within 5 days of onset of symptoms Remdesivir Give as IV infusions for 3 days in health care facility   Severe to critical COVID 19 requiring oxygen administration in any form   1.     Dexamethasone IV 2.     Remdesivir 3.     IL-6 receptor blocking agent like Tocilizumab 4.     JAK stat signalling pathway block like Baricitnib or Tofacitnib 5.     Enoxaparin in elevated D dimer levels with documented thromboembolism. Prevention of DVT with enoxaparin for all hospitalized patients Post-Exposure Prophylaxis (PEP) Evusheld (tixagevimab/cilgavimab) remains an option where effective against circulating variants, pending local guidelines. Step up Oxygen Therapy Non-invasive ventilation as the initial strategy for hypoxic patients High-flow nasal oxygen Early intubation for patients with refractory hypoxia or progressive respiratory failure Anticoagulation: -Prophylactic-dose anticoagulation for all hospitalized COVID-19 patients unless contraindicated. -Therapeutic-dose anticoagulation for selected cases with documented thrombosis or high D-dimer levels.  

Medicine, NEET PG

Cough syrup Contamination| What is Diethylene Glycol?

2-Minute Read #Coughsyrupdeath #NEET #NEETPG #FMG #INICET DEG diethylene Glycol is an industrial solvent and is part of car engine hydraulic fluid as well. Its use is well known but the safe limit of usage has to be known to doctors. DEG causes Acute tubular necrosis and leads to acute kidney injury. Recent report in Gujrat, Kheda where 5 children died allegedly by consumption of contaminated cough syrup is a tip of iceberg and such cases must be investigated thoroughly without bias and report made public and especially to health professionals. In 2022, WHO had passed scathing remarks against Indian drug manufacturing processes after death of children in Gambia again allegedly by consumption of cough syrup that did not mean quality criteria. A recent report by Central drugs standards control organization reports that out of 2104 samples testes in labs, a huge 128 which is 6% failed the quality tests.  International standards allow not more than 0.1 g per 100 ml of syrup which is not abided by some manufacturers leading to renal subtype of acute kidney injury. So what should you know about ethylene glycol and diethyl glycol for your practice and exams? Both compounds are metabolized by alcohol dehydrogenase and cause high anion gap metabolic acidosis and increased osmolal gaps. DEG metabolism leads to production of EG metabolism leads to production of 1.   2-hydroxyacetic acid 2.      Digylcolic acid 1.       Glycolic acid 2.      Oxalic acid These products then lead to crystallization of calcium oxalate crystals and leads to Acute Kidney Injury and also liver failure. Complete oxidation of ethylene glycol will depress the TCA cycle leading to lactic acid production (Type A lactic acidosis). Antidote is Fomepizole (Not FDA approved). Preference is based on efficacy and lower side effects as compared to Ethanol. Supportive management and hemodialysis may be required. Antidote treatment criteria: Serum ethylene glycol concentration > 62 mg/dl Documented history of ingestion with osmolal gap> 23 mOSM kg H20 Documented history of ingestion plus any 2 of the following a.      pH < 7.3 b.      Serum Bicarbonate < 20 mmol c.      Osmolal Gap > 25 mOsm Kg H20 d.      Presence of urinary oxalate crystals

Medicine, NEET PG

Neurology must know topic

2-Minute Read #NEETPG #NEETSS #INICET Tauopathies   Synucleinopathies   Mnemonic: ACP- DP3 Alzheimer Corticobasal syndrome Progressive supranuclear gaze Palsy Down Syndrome Pantothenate kinase associated degeneration Punch Drunk syndrome Post encephalitis Parkinsonism Mnemonic: PM- Autonomy For DoctoR Parkinson disease Multiple system atrophy Pure Autonomic failure Dementia with Lewy bodies REM behavior disorder

Medicine, NEET PG, NExT, NExT Exam

The Future of Anti-Hypertensive Therapy Explained

Once in 6 Months Blood Pressure Injection: The Future of Anti-Hypertensive Therapy Explained High blood pressure affects millions of people in India — and nearly 1 in 4 adults lives with hypertension, many without knowing it. The real challenge is not just treatment, but taking medicines regularly. Now imagine controlling blood pressure with just two injections per year. A new investigational therapy called zilebesiran may make this possible. Let’s understand it in simple language — clinically relevant, exam-focused, and easy to remember.   Featured Snippet: What Is the Once-in-6-Months Blood Pressure Injection? The once-in-6-months blood pressure injection refers to zilebesiran, an investigational RNA-interference therapy that lowers blood pressure by reducing liver production of angiotensinogen, a key component of the RAAS pathway. A single subcutaneous injection may provide blood pressure control for up to 6 months. 🇮🇳 Why This Matters: Hypertension in India Around 25–30% of Indian adults have hypertension. Many remain undiagnosed or irregular with treatment. Poor medication adherence leads to stroke, heart failure, and kidney disease. This makes long-acting therapies extremely interesting for the future of cardiovascular care. Related reading: [Hypertension management guide] (internal link)   Really? A Once-in-6-Months Anti-Hypertensive Drug? Yes — and this is what makes zilebesiran unique. Unlike conventional drugs that block hormones after formation, this drug works at the gene expression level. Daily pills block RAAS… RNAi stops RAAS from being born.   Mechanism of Action of Zilebesiran Target Liver-produced angiotensinogen (AGT) Method RNA interference (gene silencing) Effect ↓ Angiotensinogen ↓ Angiotensin II formation ↓ Vasoconstriction ↓ Blood pressure This means the drug acts upstream in the RAAS pathway, creating prolonged suppression. Related reading: [RAAS system explained simply] (internal link) Why Only Twice a Year? RNA-interference molecules remain active inside cells for a long time. Because of prolonged intracellular action: One subcutaneous injection suppresses AGT production for ~6 months. Dosing becomes biannual instead of daily. This mirrors what happened in diabetes care when therapy shifted from daily insulin to weekly injections. Clinical Trial Evidence — KARDIA Trials Phase II Study Highlights Double-blind, placebo-controlled trial 672 patients with hypertension Average baseline SBP: 143 mm Hg Key Findings Significant reduction in systolic BP vs placebo Additional benefit on top of standard medications BP lowering sustained for up to 6 months after one dose In some studies, the effect was similar to adding another oral antihypertensive drug. Why Is This a Big Deal? Solves adherence problems: Many patients forget daily pills. Twice-yearly injections could transform compliance. Continuous blood pressure control: No missed doses means more stable BP. Potential use in high-risk patients: Especially those uncontrolled despite multiple medications.   Limitations (Important Clinical Perspective) Still investigational (not routine therapy yet) Long duration means limited dose adjustment Side effects, if any, may persist longer Expected to be costlier initially So no — this does NOT replace current BP medicines yet.   Frequently Asked Questions (FAQ) ❓ What is the once-in-6-months BP injection? It is zilebesiran, an investigational RNA-interference drug that lowers blood pressure by reducing angiotensinogen production in the liver. Is zilebesiran available in India? No. It is currently under clinical trials and not yet approved for routine use. How does it differ from ACE inhibitors or ARBs? ACE inhibitors block hormone action, whereas zilebesiran prevents hormone production upstream. Who may benefit in the future? Patients with poor medication compliance or resistant hypertension may benefit if approved. Is it better than regular tablets? Not necessarily — current drugs remain effective and affordable.   Quick Summary Box Feature Zilebesiran Type RNA interference therapy Target Hepatic angiotensinogen Route Subcutaneous injection Frequency Every 6 months Status Investigational (Phase III underway) Major Advantage Improved adherence   Conclusion Will this replace daily BP tablets? Not yet. But it may represent the next evolution of hypertension treatment — where technology helps solve the biggest real-world problem: patients forgetting medicines. The future of cardiovascular pharmacology is moving toward long-acting, precision-based therapies — and zilebesiran may be one of the first steps in that direction.   References World Health Organization (WHO) ICMR Hypertension Data American College of Cardiology (ACC) trial presentations  

NEET PG

Example Post for WordPress

This is a sample post created to test the basic formatting features of the WordPress CMS. Subheading Level 2 You can use bold text, italic text, and combine both styles. Bullet list item #1 Item with bold emphasis And a link: official WordPress site Step one Step two Step three This content is only for demonstration purposes. Feel free to edit or delete it.

Medical, NEET PG

Motor neuron disease and amyotrophic lateral sclerosis

In this post we’ll break down the major types of MNDs, compare their clinical features and highlight points crucial for competitive exams like NEET PG, INI-CET, and FMGE. Core issue is combination of UMN and LMN lesion findings coexistent in a same patient for ALS. Physicist Stephen hawking was the longest living survivor of this fatal disorder that ultimately causes demise due to diaphragmatic paralysis. As bonus tip learn differences between AIDP and CIDP in 2 minutes at the bottom of this article. Comparison of Major Motor Neuron Disease  Disease  UMN involvement  LMN involvement  Key features  Onset & Progression  Age of Onset  Prognosis  Amyotrophic lateral Sclerosis (ALS) √ √ Mixed signs: spasticity + fasciculations; bulbar signs common Gradual onset, relentless progression 40-70 years Fatal within 3-5 years ( respiratory failure) Primary Lateral Sclerosis  √ X Pure UMN signs: spasticity, hyperreflexia, Babinski sign: no fasciculations Very slow progression >50 years Relatively benign Progressive muscular Atrophy (PMA) X √ Pure LMN signs; muscle wasting, fasciculations, flaccid weakness Gradual 30-60 years Better than ALS but can evolve into ALS Spinal muscular Atrophy (SMA) X √ Symmetrical LMN weakness, hypotonia, tongue fasciculations (esp. in infants) Depends on type (infantile to adult) Infancy to adulthood Varies (SMA type I is fatal in infancy) Progressive Bulbar Palsy  √ (bulbar UMNs) √ (bulbar LMNs) Dysarthria, dysphagia, tongue atrophy, emotional lability Often progresses to ALS 40-70 years Poor Pseudobulbar Palsy  √ X Dysarthria, dysphagia, emotional lability, but no tongue wasting or fasciculations Often associated with bilateral stroked / MS Older adults Variable   Key Clinical Differences  ALS (Amyotrophic lateral sclerosis) Hallmark: Combination of UMN and LMN signs in multiple regions Buzzwords: Fasciculations + spasticity: tongue atrophy; split hand sign PLS (Primary Lateral Sclerosis)  Hallmark: Pure UMN involvement Clue: No Fasciculations or muscle wasting PMA ( Progressive Muscular Atrophy Hallmark: Pure LMN disease Buzzwords: Muscle atrophy, areflexia, fasciculations, no spasticity May progress to ALS over time. SMA (Spinal Muscular Atrophy)  Genetics: Autosomal recessive, SMN1 gene mutation Types: Type I (Werdnig-Hoffmann): Infantile, floppy baby, fatal in 1st year Type II: Childhood onset Type III: (Kugelberg-Welander): Adolescent / adult onset Type: IV: Adult form, mildest   Progressive Bulbar Palsy Vs Pseudobulbar Palsy  Feature  Progressive Bulbar  Pseudobulbar  Site CN IX – XII (LMN) UMN to bulbar nuclei Tongue Atrophy, fasciculations Small spastic, no atrophy Reflexes Absent gag reflex Exaggerated jaw jerk Emotional lability Present Present Association May be variant of ALS Often bilateral strokes /MS   Important Exam Points  Most common MND: ALS ALS Affects both UMN and LMN – a key distinguishing feature Fasciculations + spasticity: Think ALS Tongue fasciculations in infants: Think SMA type I No sensory involvement is typical in MNDs. Frontotemporal dementia may coexist with ALS (especially C9 or F72 mutation) Riluzole is the only FDA – approval drug for ALS – prolongs survival by ~3 months. Recent Advances  Risdiplam for SMA Type: Oral SMN2 splicing modifier Mechanism: Increases production of functional SMN protein via enhanced SMN2 splicing Route: Oral syrup taken daily Age: Approved for infants (>2 months), children, and adult Gene therapy for SMA (Type I) with nusinersen and onasemnogene abeparvovec has revolutionized prognosis in children. Edaravone has been added as a treatment option in some ALS cases.   Bonus Tip  Comparison: AIDP vs CIDP Feature AIDP (Acute Inflammatory Demyelinating Polyradiculoneuropathy) CIDP (chronic Inflammatory Demyelinating Polyradiculoneuropathy)  Full form  Acute inflammatory demyelinating polyradiculoneuropathy Chronic Inflammatory Demyelinating Polyradiculoneuropathy Type  Most common variant of GBS Chronic form Onset Acute (subtype of GBS) Chronic (≥ weeks) Progression  Rapid (Similar to GBS) Slowly progressive or relapsing Weakness Ascending symmetric Similar but slower, often proximal and distal Reflexes  Absent or decreased Absent or decreased CSF Same as GBS Same ( mildly elevated protein, low WBC) Nerve Conduction  Demyelinating Demyelinating Treatment  IVIG or plasmapheresis Steroids IVIG, plasmapheresis (long -term)  

Medical, NEET PG

Irritable bowel Syndrome (IBS): A Practical Guide for Clinicians

Irritable Bowel Syndrome (IBS) is one of the most common functional gastrointestinal disorders encountered in clinical practice, yet it remains a diagnosis of exclusion and often misunderstood. It affects 10-15% of the global population, disproportionately impacting quality of life while posing a diagnostic challenge due to symptom overlap with inflammatory bowel disease (IBD). In this post, we’ll explore the pathophysiology, clinical features, diagnosis, and treatment of IBS with a special focus on dietary interventions (FODMAPs) and pharmacological options for IBS-C (constipation – predominant) and IBS-D (diarrhea- predominant) variants. We’ll also clarify key differences between IBS and IBD, a common source of confusion in clinical settings. What is IBS? IBS is chronic functional GI disorder characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of any identifiable structural or biochemical cause. Rome IV Criteria: Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with ≥ of the following: Related to defection Change in frequency of stool Change in form (appearance) of stool How to asses appearance of stool? Use Bristol stool chart as shown below Symptom onset must be at least 6 months before diagnosis. IBS vs IBD: A common Confusion Feature IBS IBD (Crohn’s /Ulcerative Colitis)   Nature Functional disorder Organic, inflammatory disease Pathology No mucosal inflammation or ulcers Mucosal inflammation, ulceration Colonoscopy Normal Abnormal (ulcers, erythema, pseudo-polyps) Histology Normal Inflammatory infiltrates, granulomas CRP/Fecal Calprotectin Normal Elevated Red flag signs Absent May have blood in stool, weight loss Risk of colon cancer No increased risk Increased risk   Clinical pearl: Always rule out IBD, colorectal cancer, and celiac disease before labeling a patient with IBS – especially in patients >50 or with alarming symptoms like weight loss, rectal bleeding or nocturnal symptoms. Pathophysiology of IBS IBS is multifactorial and still not fully understood. Key contributing factors include: Visceral hypersensitivity Altered gut motility Gut-brain axis dysfunction Post – infectious changes Microbiota alterations Psychological stressors ( anxiety / depression) Role of Diet: FODMAPs Explained Many patients with IBS report food -related triggers. The low FODMAP Diet is a central dietary intervention. What are FODMAPs? FODMAP= Fermentable Oligosaccharides, Disaccharides, Monosacchrides, and Polyols. These are short chain carbohydrates poorly absorbed in the gut and rapidly fermented by colonic bacteria, causing bloating, gas, and diarrhea. High FODMAP foods: Oligosaccharides: Wheat, rye, onions, garlic Disaccharides: Milk, yogurt (lactose) Monosaccharide: Apples, Honey (excess fructose) Polyols: Sorbitol, mannitol (found in artificial sweeteners, some fruits) Approach: Elimination phase: 4-6 weeks of low FODMAP intake Rechallenge phase: Gradual reintroduction to identify specific triggers Maintenance phase: Personalized, less restrictive diet Evidence supports the low FODMAP diet in reducing global IBS symptoms, particularly bloating and abdominal pain. Pharmacological Management Tailored according to predominant symptoms: IBS – C (Constipation – Predominant) Drug/ Class Mechanism Notes Fiber (e.g. psyllium) Bulking agent Soluble fiber preferred over insoluble PEG (Polyethylene glycol) Osmotic laxative First- line for many patients Lubiprostone Chloride channel activator (CIC-2) Increases intestinal fluid secretion Linaclotide Guanylate cyclase – C agonist Enhances fluid secretion and motility Prucalopride 5-HT4 receptor agonist Promotility agent; used selectively   Pro tip: Avoid stimulant laxatives long-term duet to potential for tolerance and cathartic colon. IBS – D (Diarrhea- Predominant) Drug/ Class Mechanism Notes Loperamide µ-opioid receptor agonist Symptomatic relief only; does not relieve pain Alosetron 5-HT3 antagonist Used in woman with severe IBS-D; rare ischemic colitis risk Rifaximin Non-absorbable antibiotic Useful in IBS-D with bloating; 2-week course Bile acid sequestrants Binds bile acids (e.g. cholestyramine) For patients with bile acid malabsorption Eluxadoline Mixed opioid receptor modulator Avoid in patients without gallbladder or with pancreatitis risk   For pain and global symptoms Drug/ Class Role Antispasmodics Relieve abdominal cramps (e.g. dicyclomine, hyoscine) Tricyclic Antidepressants (TCAs) Modulate pain and motility (e.g. amitriptyline) SSRIs/SNRIs For patients with predominant anxiety or depression Cognitive Behavioral Therapy (CBT) Especially effective in refractory cases   Red Flag Symptoms (NOT typically of IBS) Always investigate further if any of these are present: Age >50 with new onset symptoms Nocturnal diarrhea Unintentional weight loss Rectal bleeding Iron – deficiency anemia Family history of colorectal cancer or IBD   Summary Table: IBS subtypes and management Subtype Key Features First – line Management IBS-C Pain + infrequent, hard stools Fiber, PEG, linaclotide IBS- D Pain +frequent, loose stools Loperamide, rifaximin IBS- M Mixed symptoms Symptom – directed approach IBS-U Unclassified Supportive, individualized   “The art of IBS management is not in curing, but in relieving symptoms, validating patient concerns, and enhancing quality of life.”

INICET, Medical, Medicine classes, NEET PG

Hypokalemic vs. Hyperkalemic periodic paralysis – High Yield NEET PG & INI – CET guide

Why This Topic is Important for NEET PG & INI-CET Periodic paralysis disorders are commonly tested in NEET PG and INI-CET. A solid grasp of hypokalemic and hyperkalemic periodic paralysis will help in answering questions correctly. These conditions involve ion channel activity  affecting muscle function, leading to temporary paralysis. Let’s break it down in a high-yield, exam -focused manner. What is periodic paralysis? Periodic paralysis refers to rare neuromuscular disorders characterized by episodes of muscle weakness or paralysis triggered by fluctuation in serum potassium levels.  The two main types are mentioned in the tabular format highlighting key differences. Mnemonic to remember “HYPO has HIGH triggers, HYPER has Low Triggers” HYPO Kalemic Paralysis = HIGH Sugar & Carb intake causes an attack . HYPER Kalemic paralysis = LOW Food intake (Fasting) triggers the episode. Key differences – High – Yield Table Feature Hypokalemic Periodic Paralysis Hyperkalemic Periodic paralysis Cause Mutation in CACNA1S/SCN4A gene Primary answer as calcium channel defect Mutation in SCN4A gene Primary answer as sodium channel defect Serum potassium during attack Low (<3.5 mEq/L) High (>5.0 mEq/L) Triggers High -carb meals, exercise, stress Fasting, rest after exercise Onset Teenage years (10-20 years) Early childhood Duration of Attack Hours to days Minutes to hours Reflexes Reduced Normal Treatment Potassium supplementation, avoiding triggers Glucose, diuretics (thiazides)   Clinical cases to remember Hypokalemic Periodic Paralysis Hyperkalemic Periodic Paralysis A 15-year-old male wakes up with sudden muscle weakness after eating a large pizza and soda the previous night Blood tests show low serum potassium ( 2.5 mEq/L) A 6-year-old child experiences muscle weakness after skipping breakfast. Symptoms resolve spontaneously after a few hours. Blood tests show elevated potassium ( 5.6 mEq/L).   Diagnosis & Investigations Serum potassium levels during an attack Electromyography (EMG): Shows myotonic discharges in Hyper PP Genetic testing: Confirms mutations in SCN4A (Hyper PP) and CACNA1S/SCN4A (Hypo PP) Exercise Test: Potassium levels drop in Hypo PP and rise in Hyper PP   Treatment Approach – High Yield Table Condition Acute attack Management Long-Term prevention Hypokalemic PP Oral /IV potassium Avoid high-carb meals, Acetazolamide Hyperkalemic PP Glucose + insulin, diuretics Low potassium, diet, acetazolamide   Exam Pearls – Must – Know for NEET PG & INI- CET Hypokalemic PP is often linked to thyrotoxic periodic paralysis – commonly seen in Asian populations. Hyperkalemic PP is associated with myotonia (delayed muscle relaxation after contraction). Acetazolamide is used in both conditions as it stabilizes ion channels but can worsen type 2 RTA.   📌Related High – Yield Topics to Read click on this link https://marwahmedicine.com/newsite/blogs/ Suggested reading for doctors sitting for NEET PG and INICET examination from these blog posts 📌Barrter vs. Gitelman syndrome 📌 Renal Tubular Acidosis 📌 Electrolyte disorders – Quick Mnemonics& Cases

Scroll to Top